US2016220524A1PendingUtilityA1

Compositions of small molecule therapeutics

44
Assignee: DAMAJ BASSAM BPriority: May 4, 2010Filed: Jan 29, 2015Published: Aug 4, 2016
Est. expiryMay 4, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:Bassam DamajRichard Martin
A61K 9/0095A61K 31/655A61K 31/635A61K 47/18A61K 47/14A61K 31/7008A61K 31/451A61K 31/549A61K 31/138A61K 31/165A61K 9/4858A61K 31/4515A61K 9/0019A61K 31/4439A61K 31/445A61K 31/221A61K 31/337A61P 35/00A61K 47/10A61K 31/341A61K 31/335
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions containing a small molecule therapeutic and an alkyl N,N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N,N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic.

Claims

exact text as granted — not AI-modified
1 - 30 . (canceled) 
     
     
         31 . An oral or subcutaneously injectable composition comprising a small molecule therapeutic, an alkyl N,N-disubstituted-amino acetate, and one or more pharmaceutically acceptable carriers. 
     
     
         32 . The composition in accordance with  claim 31  wherein the small molecule therapeutic is selected from the group consisting of a taxane, and a compound classified under the Biopharmaceutics Classification System (BCS) in at least one of Class 2, Class 3 or Class 4. 
     
     
         33 . The composition in accordance with  claim 32  wherein the taxane is a member of the group consisting of paclitaxel, docetaxel, tesetaxel, and mixtures thereof. 
     
     
         34 . The composition in accordance with  claim 32  wherein the compound is a member of BCS Class 2. 
     
     
         35 . The composition in accordance with  claim 34  wherein the compound is selected from the group consisting of lansoprazole, haloperidol, sulfasalazine, and glibenclamide. 
     
     
         36 . The composition in accordance with  claim 32  wherein the compound is a member of BCS Class 3. 
     
     
         37 . The composition in accordance with  claim 36  wherein the compound is selected from the group consisting of atenolol, glucosamine or salt thereof, and cimetidine. 
     
     
         38 . The composition in accordance with  claim 32  wherein the compound is a member of BCS Class 4. 
     
     
         39 . The composition in accordance with  claim 38  wherein the compound is selected from the group consisting of furosemide, chlorothiazide, and hydrochlorothiazide. 
     
     
         40 . The composition in accordance with  claim 31  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         41 . The composition in accordance with  claim 31  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         42 . The composition in accordance with  claim 31  wherein the small molecule therapeutic is a taxane and the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         43 . The composition in accordance with  claim 31  wherein the small molecule therapeutic is a taxane and the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         44 . The composition in accordance with  claim 31  wherein the small molecule therapeutic is paclitaxel and the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         45 . The composition in accordance with  claim 31  wherein the small molecule therapeutic is a paclitaxel and the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         46 . An oral or subcutaneously injectable composition comprising a taxane, an alkyl N,N-disubstituted-amino acetate, and one or more pharmaceutically acceptable carriers. 
     
     
         47 . The composition in accordance with  claim 46  wherein the taxane is a member of the group consisting of paclitaxel, docetaxel, tesetaxel, and mixtures thereof. 
     
     
         48 . The composition in accordance with  claim 46  wherein the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         49 . The composition in accordance with  claim 46  wherein the alkyl N,N-disubstituted amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         50 . The composition in accordance with  claim 46  wherein the taxane is paclitaxel and the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         51 . The composition in accordance with  claim 46  wherein the taxane is paclitaxel and the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         52 . The composition in accordance with  claim 34  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         53 . The composition in accordance with  claim 35  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         54 . The composition in accordance with  claim 36  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         55 . The composition in accordance with  claim 37  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         56 . The composition in accordance with claim  8  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         57 . The composition in accordance with claim  7  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride. 
     
     
         58 . The composition in accordance with claim  9  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate. 
     
     
         59 . The composition in accordance with claim  9  wherein the alkyl N,N-disubstituted-amino acetate is dodecyl 2-(N,N-dimethylamino) propionate hydrochloride.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.